PHARMA MAR overview

Life Science Alliance journal publishes results of plitidepsin in patients with COVID-19, which includes additional data on its antiviral activity against Delta and Omicron variants - The final results of the APLICOV-PC study (Phase I-II), which were initially released last May and which the Company shared with the scientific community, demonstrate the safety of plitidepsin's use in patients with COVID-19 and postulate a positive therapeutic impact on the evolution of the disease. - PharmaMar...

PharmaMar and Jazz Pharmaceuticals Announce Initiation of Confirmatory Phase 3 Clinical Trial of Zepzelca® (lurbinectedin) for the Treatment of Patients with Relapsed Small Cell Lung Cancer The confirmatory trial is designed to secure full approval in the U.S. and serve as a registrational trial for the European Medicines Agency The multi-center, open-label global trial will enroll 705 patients from over 100 centers mainly in North America and Europe PR Newswire MADRID and DUBLIN, Dec. 13, 2021...

PharmaMar signs a licensing and commercialization agreement with Lotus Pharmaceutical for lurbinectedin in Taiwan PR Newswire MADRID, Nov. 11, 2021 MADRID , Nov. 11, 2021 /PRNewswire/ -- PharmaMar S.A. (MSE: PHM) has announced today a licensing agreement with Lotus Pharmaceutical CO., LTD. (TWSE:1795) to commercialize the anticancer drug lurbinectedin in Taiwan . Under the terms of the license and commercialization agreement, PharmaMar will receive a non-disclosed upfront payment and will be...

Jazz Pharmaceuticals and PharmaMar Announce Results of ATLANTIS Phase 3 Study Evaluating Zepzelca™ in Combination with Doxorubicin for Patients with Small Cell Lung Cancer Following One Prior Platinum-containing Line PR Newswire DUBLIN, Dec. 3, 2020 DUBLIN , Dec. 3, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ), along with its partner, PharmaMar (MSE: PHM), today announce results from the ATLANTIS Phase 3 multicenter, randomized, controlled study evaluating Zepzelca™...

PharmaMar Announces the U.S. FDA Approval of lurbinectedin (Zepzelca™) for the Treatment of Metastatic Small Cell Lung Cancer PR Newswire MADRID, June 16, 2020 - Lurbinectedin is approved under "Accelerated Approval" based on overall response rate and duration of response demonstrated in an open-label, monotherapy clinical trial. - The anti-tumor compound lurbinectedin will be marketed under the brand name Zepzelca ™ . - Lurbinectedin is expected to be made commercially available in the U.S....

PharmaMar Has Announced That the Spanish Medicines Agency Has Authorized the APLICOV-PC Clinical Trial With Aplidin® (Plitidepsin) for the Treatment of Patients With COVID-19 - The objective of the trial is to evaluate the efficacy and safety of plitidepsin in patients with COVID-19 requiring hospital admission - Plitidepsin recently obtained positive results from in vitro studies on the human HCoV-229E coronavirus, carried out at the National Biotechnology Center (Centro Nacional de...